Biologics: Targets & Therapy (May 2021)
How Can We Engineer CAR T Cells to Overcome Resistance?
Abstract
Maya Glover,1 Stephanie Avraamides,2 John Maher1– 4 1Leucid Bio Ltd., Guy’s Hospital, London, SE1 9RT, UK; 2King’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Hospital, London, SE1 9RT, UK; 3Department of Clinical Immunology and Allergy, King’s College Hospital NHS Foundation Trust, London, SE5 9RS, UK; 4Department of Immunology, Eastbourne Hospital, Eastbourne, East Sussex, BN21 2UD, UKCorrespondence: John Maher Tel +44 207 188 1468Fax +44 207 188 0919Email [email protected]: Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.Keywords: chimeric antigen receptor, cancer, immunotherapy, T-cell, resistance
